Pfenex to Participate in the Oppenheimer Fall Summit
September 10 2019 - 4:05PM
Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and
licensing biotechnology company focused on leveraging its Pfēnex
Expression Technology® to improve protein therapies for unmet
patient needs, today announced that Eef Schimmelpennink, President
and Chief Executive Officer, and Susan Knudson, Chief Financial
Officer, will be participating in one-on-one investor meetings at
the Oppenheimer Fall Summit focused on specialty pharma and rare
disease companies, taking place at the Parker Hotel in New York
City on September 23rd - 24th.
Oppenheimer & Co. Fall Summit
Date: |
September 24th |
|
|
Format: |
One-on-One Meetings |
About Pfenex Inc.
Pfenex is a clinical-stage development and licensing
biotechnology company focused on leveraging its Pfēnex Expression
Technology® to develop and improve protein therapies for unmet
patient needs. Using the patented Pfēnex Expression Technology
platform, Pfenex has created an advanced pipeline of potential
therapeutic equivalents, vaccines, biologics and biosimilars.
Pfenex’s lead product candidate is PF708, a therapeutic equivalent
candidate to Forteo® (teriparatide) for the treatment of
osteoporosis. In addition, Pfenex is developing hematology/oncology
products, including PF743, a recombinant crisantaspase, and PF745,
a recombinant crisantaspase with half-life extension technology, in
collaboration with Jazz Pharmaceuticals. Pfenex also uses its
Pfēnex Expression Technology platform to produce CRM197, a
diphtheria toxoid carrier protein used in prophylactic and
therapeutic vaccines.
Pfenex investors and others should note that Pfenex announces
material information to the public about Pfenex through a variety
of means, including its website (http://www.pfenex.com/), its
investor relations website (http://pfenex.investorroom.com/), press
releases, SEC filings, public conference calls, corporate Twitter
account (https://twitter.com/pfenex), Facebook page
(https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/),
and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in
order to achieve broad, non-exclusionary distribution of
information to the public and to comply with its disclosure
obligations under Regulation FD. Pfenex encourages its investors
and others to monitor and review the information Pfenex makes
public in these locations as such information could be deemed to be
material information. Please note that this list may be updated
from time to time.
Company Contact: Susan A. KnudsonChief
Financial Officer(858) 352-4324sknudson@pfenex.com
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Apr 2023 to Apr 2024